EGFR and non-small cell lung carcinoma: Consequently, current guidelines do not recommend combining tyrosine kinase inhibitors with ICI for EGFR-mutant NSCLC patients, underscoring the urgent need to develop alternative immunotherapeutic approaches, such as CAR-T cell therapy, for this subgroup.